HIK Hikma Pharmaceuticals Plc

RNS Number:0109M
Hikma Pharmaceuticals Plc
17 January 2008





NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO 
THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE UNITED ARAB EMIRATES



Hikma Pharmaceuticals PLC

17 January 2008





HIKMA PHARMACEUTICALS PLC

RESULT OF PLACING OF NEW ORDINARY SHARES

PLACING PRICE SET AT 480 PENCE PER NEW ORDINARY SHARE


Hikma Pharmaceuticals PLC ("Hikma") announces that, further to the announcement on 17 January 2008 (the "Announcement"),
a total of 17 million new ordinary shares of 10 pence each in Hikma (the "Placing Shares") have been placed by Merrill 
Lynch International ("Merrill Lynch") and Citigroup Global Markets U.K. Equity Limited ("Citi") at a price of 480 pence 
per Placing Share, raising gross proceeds of approximately �81.6 million (the "Placing").  As part of the Placing 5.23 
million Placing Shares have been placed with Darhold Limited at the Placing Price and 332,663 Placing Shares have been 
placed with the Darwazah family and other connected individuals at the Placing Price.  The Placing Shares being issued 
represent 9.9 per cent of Hikma's issued ordinary share capital prior to the Placing.

The Placing will enable the Hikma group to reduce borrowings incurred in connection with its JD116.0 million ($163.6 
million) acquisition of Arab Pharmaceutical Manufacturing Company, announced on 10 December 2007, thereby providing 
Hikma with increased flexibility to finance future growth.

Application will be made for, and the Placing is conditional upon, inter alia, admission of the Placing Shares to the 
Official List of the Financial Services Authority and admission to trading of the Placing Shares by London Stock 
Exchange plc on its main market for listed securities  (together, "Admission"). It is expected that Admission will 
become effective and that dealings will commence in the Placing Shares at 8:00am on 22 January 2008.  Subject to the 
conditions being satisfied, the Placing Shares will be issued credited as fully paid and will rank pari passu in all 
respects with Hikma's existing ordinary shares.



Enquiries


Hikma Pharmaceuticals PLC

Susan Ringdal                                               Direct Line: +44 20 7399 2760
Investor Relations Director                                 Mobile: +44 7776 477 050

Merrill Lynch International

Lorcan O'Shea                                               +44 20 7996 5949
Andrew Fairclough                                           +44 20 7996 0469
Aukse Jurkute                                               +44 20 7995 3700

Citigoup Global Markets U.K. Equity Limited

Andrew Chapman                                              +44 20 7986 0505
Ronan Veale                                                 +44 20 7986 0433
Darrell Uden                                                +44 20 7986 0410

Brunswick Group LLP

Jon Coles                                                   +44 20 7404 5959
Justine McIlroy


General


This announcement is being issued by and is the sole responsibility of Hikma
Pharmaceuticals plc. No representation or warranty, express or implied, is or
will be made as to, or in relation to, and no responsibility or liability is or
will be accepted by the Managers or by any of their respective affiliates or
agents as to or in relation to, the accuracy or completeness of this
announcement, or any other written or oral information made available to or
publicly available to any prospective investor or its advisers, and any
liability therefore is hereby expressly disclaimed.


Merrill Lynch and Citi are each acting exclusively for the Company and no-one
else in relation to the Placing and will not be responsible to any person other
than the Company for providing the protections afforded to their respective
clients or for providing advice in relation to the Placing or in relation to the
contents of this announcement or any other transaction, arrangement or matter
referred to herein.



This announcement is for information purposes only and does not constitute an
offer to issue or sell, or the solicitation of an offer to subscribe for or
acquire, any securities to any person in any jurisdiction, including without
limitation in the United States, Canada, Australia or Japan.  This announcement
and the information contained herein is not for publication or distribution,
directly or indirectly, to persons in the United States, Canada, Australia,
Japan, the United Arab Emirates (the "UAE") or in any jurisdiction in which such
publication or distribution is unlawful.



The securities referred to in this announcement have not been, nor will they be,
registered under the US Securities Act of 1933, as amended (the "Securities Act
") or with any securities regulatory authority of any State or other
jurisdiction of the United States, and accordingly may not be offered or sold
within the United States except pursuant to an exemption from, or in a
transaction not subject to, registration under the Securities Act.  No public
offering of the securities referred to herein will be made in the United States.
Any offering to be made in the United States will be made to a limited number of
"qualified institutional buyers" pursuant to an exemption from registration
under the Securities Act in a transaction not involving any public offering. The
Placing Shares are being offered and sold outside the United States in
accordance with Regulation S under the Securities Act.



This announcement is not intended to constitute an offer, sale or delivery of
shares or other securities under the laws of the UAE. The securities referred to
herein have not been and will not be registered under Federal Law No. 4 of 2000
Concerning the Emirates Securities and Commodities Authority and the Emirates
Security and Commodity Exchange, or with the UAE Central Bank, the Dubai
Financial Market, the Abu Dhabi Securities market or with any other UAE
exchange. The Placing, the Placing Shares and interests therein have not been
approved or licensed by the UAE Central Bank or any other relevant licensing
authorities in the UAE, and do not constitute a public offer of securities in
the UAE in accordance with the Commercial Companies Law, Federal Law No. 8 of
1984 (as amended) or otherwise.



The Placing Shares are not being offered or sold in the Dubai International
Financial Centre (the "DIFC") unless such offer is (a) deemed to be an ''Exempt
Offer'', made in accordance with the Offered Securities Rules (the ''Rules'') of
the Dubai Financial Services Authority (the "DFSA"); (b) made to Qualified
Investors as defined in the Rules; and (c) made through a duly authorised firm
in the DIFC.



This announcement relates to an exempt offer in accordance with the Rules.  This
announcement is intended for distribution only to persons of a type specified in
those rules.  It must not be delivered to, or relied on by, any other person.
The DFSA has no responsibility for reviewing or verifying any documents in
connection with Exempt Offers.  The DFSA has not approved this announcement or
taken steps to verify the information set out in it, and has no responsibility
for it.  The securities to which this announcement relates may be illiquid and/
or subject to restrictions on their resale.  Prospective investors in the
Placing Shares should conduct their own due diligence on the Placing Shares.
Prospective investors who do not understand the contents of this announcement
should consult an authorised financial adviser.



Certain statements made in this announcement are forward looking statements.
Such forward looking statements are based on current expectations and numerous
assumptions regarding the Company's present and future business strategies and
the environments in which the Company will operate in the future. Such
assumptions may or may not prove to be correct and actual results and
performance could differ materially from any expected further results or
performances, express or implied, by the forward looking statements. Factors
that might cause forward looking statements to differ materially from actual
results include, among other things, changes in global, political, economic,
business, competitive, market and regulatory forces, future exchange and
interest rates and future business combinations or disposals. The Company
expressly disclaims and assumes no responsibility to update or revise any of the
forward looking statements contained in this announcement to reflect any change
in the Company's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

ROIFKOKPNBKDFDD

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024